Plus Therapeutics receives Nasdaq delisting notice; plans appeal to stay listing

PLUS THERAPEUTICS, INC.

Nasdaq notified on Sept 5, 2024 that company failed to regain compliance with minimum $2.5M stockholders' equity rule.
Company intends to timely appeal, which automatically stays suspension/delisting pending hearing.
Prior disclosure: stockholders' equity was ($1.348M) as of Dec 31, 2023.
No assurance that Nasdaq Hearings Panel will grant continued listing or extension.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.